405 related articles for article (PubMed ID: 12794818)
1. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
[TBL] [Abstract][Full Text] [Related]
2. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
3. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
[TBL] [Abstract][Full Text] [Related]
4. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
[TBL] [Abstract][Full Text] [Related]
5. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
7. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience.
Yocum DE; Furst DE; Bensen WG; Burch FX; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisememandle W; Mekki QA;
Rheumatology (Oxford); 2004 Aug; 43(8):992-9. PubMed ID: 15014199
[TBL] [Abstract][Full Text] [Related]
8. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
[TBL] [Abstract][Full Text] [Related]
9. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study.
Jaimes-Hernández J; Robles-San Román M; Suárez-Otero R; Dávalos-Zugasti ME; Arroyo-Borrego S
J Rheumatol; 2004 Feb; 31(2):235-7. PubMed ID: 14760790
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP
Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.
Dougados M; Emery P; Lemmel EM; de la Serna R; Zerbini CA; Brin S; van Riel P
J Rheumatol; 2003 Dec; 30(12):2572-9. PubMed ID: 14719196
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
Poór G; Strand V;
Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
17. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
Kremer J; Genovese M; Cannon GW; Caldwell J; Cush J; Furst DE; Luggen M; Keystone E; Bathon J; Kavanaugh A; Ruderman E; Coleman P; Curtis D; Kopp E; Kantor S; Weisman M; Waltuck J; Lindsley HB; Markenson J; Crawford B; Fernando I; Simpson K; Strand V
J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
[TBL] [Abstract][Full Text] [Related]
18. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
19. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
